Flaherty & Crumrine’s Exelon EXC Stock Holding History

Flaherty & Crumrine’s Portfolio EXC Stock Details EXC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-105,150	Closed	-$2.52M	–	10
2014 Q1	$2.52M	Hold	105,150	–	–	1.61%	9
2013 Q4	$2.05M	Hold	105,150	–	–	1.38%	9
2013 Q3	$2.22M	Hold	105,150	–	–	1.38%	10
2013 Q2	$2.31M	Buy	+105,150	New	+$2.55M	1.42%	9

Other funds holding EXC

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Institutional Capital Chicago, Illinois $6.75B AUM 3.44% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Flaherty & Crumrine's EXC Position: Q2 2014 in Review

Flaherty & Crumrine sold out of Exelon (EXC) in Q2 2014, closing a stake of 105,150 shares — an estimated $2.52M sold.

Flaherty & Crumrine first reported a position in EXC in Q2 2013 and held it in 4 quarters. The position peaked at $2.52M in Q1 2014. 731 funds tracked by Wall St. Rank hold EXC as of Q2 2014.

Flaherty & Crumrine reported no remaining Exelon position as of Q2 2014 after selling out during the quarter.
Flaherty & Crumrine sold 105,150 Exelon shares in Q2 2014, an estimated $2.52M.
Flaherty & Crumrine first reported a position in Exelon in Q2 2013 and held it in 4 quarters.
Flaherty & Crumrine's Exelon position peaked at $2.52M in Q1 2014.
731 funds tracked by Wall St. Rank held Exelon as of Q2 2014.

Based on Flaherty & Crumrine's 13F filing for Q2 2014, filed 14 Aug 2014.